Fidelis Capital Partners LLC Purchases 4,026 Shares of Johnson & Johnson (NYSE:JNJ)

Fidelis Capital Partners LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 30.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,207 shares of the company’s stock after acquiring an additional 4,026 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Johnson & Johnson were worth $2,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in JNJ. First Citizens Financial Corp increased its position in shares of Johnson & Johnson by 8.1% during the 3rd quarter. First Citizens Financial Corp now owns 8,599 shares of the company’s stock valued at $1,339,000 after purchasing an additional 645 shares during the last quarter. PineStone Asset Management Inc. increased its position in shares of Johnson & Johnson by 190.5% during the 3rd quarter. PineStone Asset Management Inc. now owns 1,494,978 shares of the company’s stock valued at $232,843,000 after purchasing an additional 980,297 shares during the last quarter. Buckingham Capital Management Inc. increased its position in shares of Johnson & Johnson by 6.5% during the 3rd quarter. Buckingham Capital Management Inc. now owns 10,703 shares of the company’s stock valued at $1,667,000 after purchasing an additional 651 shares during the last quarter. McKinley Carter Wealth Services Inc. increased its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. McKinley Carter Wealth Services Inc. now owns 18,860 shares of the company’s stock valued at $2,937,000 after purchasing an additional 114 shares during the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at approximately $838,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada dropped their price objective on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, April 15th. Finally, Morgan Stanley dropped their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Trading Down 0.7 %

Shares of NYSE JNJ opened at $148.53 on Thursday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The stock has a market capitalization of $357.92 billion, a P/E ratio of 9.26, a price-to-earnings-growth ratio of 2.46 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The business has a fifty day moving average price of $155.69 and a 200 day moving average price of $155.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.68 EPS. Equities research analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is 29.68%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.